BRNS
Barinthus Biotherapeutics
BRNS
BRNS
15 hedge funds and large institutions have $36.6M invested in Barinthus Biotherapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
15
Holders Change
-1
Holders Change %
-6.25%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
1
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$43.2K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.2K |
| 3 |
Renaissance Technologies
New York
|
+$30.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$5.38K |
Top Sellers
| 1 |
IIM
Ipswich Investment Management
Beverly,
Massachusetts
|
-$14.8K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$309 |
